27.30
price down icon2.53%   -0.71
after-market Handel nachbörslich: 27.84 0.54 +1.98%
loading

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

pulisher
Jul 23, 2025

Ultragenyx Pharmaceutical Inc. Stock Analysis and ForecastSkyrocketing profit margins - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Ultragenyx Pharmaceutical Inc. stock priceRapid portfolio appreciation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.

Jul 23, 2025
pulisher
Jul 22, 2025

RARE ACTIVE INVESTIGATION: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Ultragenyx Pharmaceutical Inc. stockUnmatched profit potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Ultragenyx Pharmaceutical (RARE) Gets a Complete Response Letter for UX111 - Insider Monkey

Jul 22, 2025
pulisher
Jul 22, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

Is Ultragenyx Pharmaceutical Inc. a good long term investmentConsistently high returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 20, 2025

11 Best All-Time Low Stocks to Buy According to Analysts - Insider Monkey

Jul 20, 2025
pulisher
Jul 20, 2025

William Blair Maintains a Buy on Ultragenyx Pharmaceutical (RARE) - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Ultragenyx Grants Restricted Stock Units to New Employees, Expands Workforce and Focus on Rare Diseases. - AInvest

Jul 20, 2025
pulisher
Jul 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 20, 2025

Did You Suffer Losses in Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 18, 2025

Shareholders Alert: Investigation Into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 18, 2025
pulisher
Jul 18, 2025

Rare Disease Leader Ultragenyx Expands Team with 45,292 Stock Grants to New Hires - Stock Titan

Jul 18, 2025
pulisher
Jul 18, 2025

RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law Firm - The Globe and Mail

Jul 18, 2025
pulisher
Jul 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Investors to Reach Out - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 18, 2025

Ultragenyx stock hits 52-week low at $26.85 By Investing.com - Investing.com Canada

Jul 18, 2025
pulisher
Jul 18, 2025

Published on: 2025-07-18 04:31:12 - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Why Ultragenyx Pharmaceutical Inc. stock is on top investor watchlistsDouble Your Capital Alerts - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Ultragenyx’s SWOT analysis: rare disease biotech stock faces pivotal trials - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Sarepta Therapeutics Announces Workforce Reductions as FDA Rejects Ultragenyx Rare Disease Drug Over Manufacturing Concerns - geneonline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Ongoing Securities Investigation into Ultragenyx Pharmaceutical Inc. (RARE)Contact Levi & Korsinsky - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 17, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Reach Out - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 17, 2025

Bank of America Securities Reiterated a Buy Rating on Ultragenyx Pharmaceutical (RARE) - Insider Monkey

Jul 17, 2025
pulisher
Jul 17, 2025

Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com

Jul 17, 2025
pulisher
Jul 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Ultragenyx Pharmaceutical Inc. (RARE) And Encourages Stockholders to Connect - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 16, 2025

Ultragenyx, Mereo in selloff after trial update on bone disorder therapy - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionMinimized Risk Trading Plan - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Ultragenyx gets Complete Response Letter for Sanfilippo syndrome gene therapy - MSN

Jul 15, 2025
$23.63
price up icon 3.30%
$36.59
price up icon 1.58%
$103.52
price up icon 0.10%
$27.57
price down icon 1.54%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.65%
Kapitalisierung:     |  Volumen (24h):